Mark L. Baum
2012
In 2012, Mark L. Baum earned a total compensation of $1.3M as Chief Executive Officer at Imprimis Pharmaceuticals.
Compensation breakdown
| Option Awards | $655,773 |
|---|---|
| Salary | $150,300 |
| Stock Awards | $520,000 |
| Total | $1,326,073 |
Baum received $655.8K in option awards, accounting for 49% of the total pay in 2012.
Baum also received $150.3K in salary and $520K in stock awards.
Rankings
In 2012, Mark L. Baum's compensation ranked 5,026th out of 11,487 executives tracked by ExecPay. In other words, Baum earned more than 56.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,026 out of 11,487 | 56th |
Division Manufacturing | 1,760 out of 4,253 | 59th |
Major group Chemicals And Allied Products | 421 out of 1,198 | 65th |
Industry group Drugs | 273 out of 920 | 70th |
Industry Pharmaceutical Preparations | 214 out of 700 | 69th |
Source: SEC filing on September 12, 2013.
Baum's colleagues
We found three more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2012.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019